Remifentanil for modified rapid sequence induction in children: a proof-of-concept study in a selected pediatric population
Abstract
Introduction: Rapid Sequence Induction (RSI) is widely used in pediatric anesthesia for children at risk of pulmonary aspiration. Modified RSI has been proposed to reduce the risk of hypoxemia during induction while maintaining airway protection. This proof-of-concept study aimed to describe peri-intubation outcomes associated with the use of intravenous bolus remifentanil during modified RSI in a selected pediatric population at risk of pulmonary aspiration. Methods: This proof-of-concept study analyzed data from pediatric patients, with at least one risk factor for pulmonary aspiration, undergoing modified RSI with remifentanil between December 2021 and August 2023. Exclusion criteria included the planned use of a neuromuscular blocking agent for RSI, preoperative hypoxemia, hemodynamic shock or difficult intubation risk factors. Remifentanil was administered by direct intravenous injection with optional prophylactic administration of atropine. Data on intubation success rates, major and minor complications and rescue treatment were collected and analyzed. Results: A total of 267 children were included (median age 8.0 years [IQR 5.0-12.0]). Successful first-attempt intubation without major complications was achieved in 92.9% (248/267; 95% CI 88.9-95.6). No major complications were reported. Nineteen patients (7.1%) required more than one intubation attempt. In multivariable analysis, age < 1-year (adjusted OR = 11.4, 95% CI 3.5-34.3; p < 0.001) and Cormack-Lehane grade ≥ 2 (adjusted OR = 10.2, 95% CI 1.8-57.2; p = 0.008) were associated with failed first-attempt intubation. Minor complications occurred in 15.7% of patients, mainly transient hypotension. Conclusion: In this proof-of-concept study of a selected pediatric population, modified RSI with remifentanil was associated with a first-attempt intubation success rate of 92.9%, with no major complications observed. These descriptive findings should be considered hypothesis-generating and support further evaluation of remifentanil-based modified RSI in prospective randomized studies.
Related
- Dose-modified methotrexate, rituximab, and temozolomide induction achieves durable remissions in PCNSL
- Prevention and Management of Pediatric Sensitive Skin Conditions in India: A Modified Delphi Consensus
- Genomic Determinants of Induction Failure and Persistent Prognostic Risk of FLT3-ITD in Pediatric Acute Myeloid Leukemia
- Neonatal and pediatric nutritional care: a modified Delphi consensus on dietary management for infants with congenital heart disease in four Middle Eastern countries
- Osteochondral lesions of the talus in the pediatric population: A practical narrative review
BibTeX
@article{pico2026remifentanil,
title = {{Remifentanil for modified rapid sequence induction in children: a proof-of-concept study in a selected pediatric population}},
author = {Julien Pico and Chrystelle Sola and Laurent Hertz and Julien Riera and Christopher Scott and Kévin Chapron and Philippe Pirat and Sophie Bringuier and Christophe Dadure},
journal = {Brazilian Journal of Anesthesiology (English Edition)},
year = {2026},
month = sep,
doi = {10.1016/j.bjane.2026.844837},
url = {https://hal.science/hal-05781813v1},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Remifentanil for modified rapid sequence induction in children: a proof-of-concept study in a selected pediatric population
AU - Julien Pico
AU - Chrystelle Sola
AU - Laurent Hertz
AU - Julien Riera
AU - Christopher Scott
AU - Kévin Chapron
AU - Philippe Pirat
AU - Sophie Bringuier
AU - Christophe Dadure
PY - 2026
DA - 2026/09/24
JO - Brazilian Journal of Anesthesiology (English Edition)
DO - 10.1016/j.bjane.2026.844837
UR - https://hal.science/hal-05781813v1
AB - Introduction: Rapid Sequence Induction (RSI) is widely used in pediatric anesthesia for children at risk of pulmonary aspiration. Modified RSI has been proposed to reduce the risk of hypoxemia during induction while maintaining airway protection. This proof-of-concept study aimed to describe peri-intubation outcomes associated with the use of intravenous bolus remifentanil during modified RSI in a selected pediatric population at risk of pulmonary aspiration. Methods: This proof-of-concept study analyzed data from pediatric patients, with at least one risk factor for pulmonary aspiration, undergoing modified RSI with remifentanil between December 2021 and August 2023. Exclusion criteria included the planned use of a neuromuscular blocking agent for RSI, preoperative hypoxemia, hemodynamic shock or difficult intubation risk factors. Remifentanil was administered by direct intravenous injection with optional prophylactic administration of atropine. Data on intubation success rates, major and minor complications and rescue treatment were collected and analyzed. Results: A total of 267 children were included (median age 8.0 years [IQR 5.0-12.0]). Successful first-attempt intubation without major complications was achieved in 92.9% (248/267; 95% CI 88.9-95.6). No major complications were reported. Nineteen patients (7.1%) required more than one intubation attempt. In multivariable analysis, age < 1-year (adjusted OR = 11.4, 95% CI 3.5-34.3; p < 0.001) and Cormack-Lehane grade ≥ 2 (adjusted OR = 10.2, 95% CI 1.8-57.2; p = 0.008) were associated with failed first-attempt intubation. Minor complications occurred in 15.7% of patients, mainly transient hypotension. Conclusion: In this proof-of-concept study of a selected pediatric population, modified RSI with remifentanil was associated with a first-attempt intubation success rate of 92.9%, with no major complications observed. These descriptive findings should be considered hypothesis-generating and support further evaluation of remifentanil-based modified RSI in prospective randomized studies.
SN - 0104-0014
ER -